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Summary
Passive	properties	of	the	myocardium	influence	diastolic	filling	and	cardiac	output.	In	heart	
failure,	changes	in	contributors	to	the	passive	properties	of	the	ventricle,	such	as	titin	and	
collagen,	and	loss	of	the	metabolic	enzyme	creatine	kinase,	increase	resistance	to	filling	
resulting	in	diastolic	dysfunction.	Pulmonary	artery	hypertension	(PAH)	arises	from	inter-
actions	between	the	pulmonary	vasculature	and	the	right	ventricle	(RV)	which	ultimately	
leads	to	RV	failure.	Beta1-	adrenergic	receptor	blockers	(BB)	act	on	the	myocardium	and	
are	beneficial	in	left	heart	failure	but	are	not	used	in	PAH.	We	investigated	whether	BB	
improved	survival	and	RV	function	in	a	rat	model	of	PAH.	Rats	were	injected	with	mono-
crotaline	(60	mg/kg)	to	induce	PAH	and	RV	failure,	or	saline	as	controls	(CON).	When	PAH	
was	established,	rats	were	treated	with	metoprolol	(10	mg/kg	per	day)	(MCT+BB)	or	vehi-
cle	(sucrose)	(MCT);	CON	were	treated	with	vehicle.	In	vivo	measurement	of	RV	compli-
ance	using	pressure–volume	catheter,	indicated	diastolic	dysfunction	in	the	RV	of	MCT	
rats	was	improved	with	BB	treatment.	Expression	of	creatine	kinase	protein	and	mRNA	
was	lower	in	MCT	rats	compared	to	CON,	with	a	trend	for	reversion	by	BB	treatment.	
Isolated	CON	RV	myocytes	had	a	positive	contraction	response	to	faster	pacing,	whereas	
it	was	negative	in	MCT.	MCT+BB	cells	had	an	intermediate	response,	indicating	improved	
ability	to	respond	to	increased	demand.	BB	improved	diastolic	function,	partially	restored	
metabolic	enzymes	and	augmented	contractility	in	PAH.	These	data	support	the	hypoth-
esis	that	BB	may	be	beneficial	in	PAH	by	supporting	RV	function.
K E Y W O R D S
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1  | DIASTOLIC DYSFUNCTION AND 
HEART FAILURE
Ventricular	 stroke	 volume	 is	 influenced	 by	 end-	diastolic	 volume	
through	 the	 Frank-	Starling	 mechanism.	 This	 dictates	 that	 as	 the	
ventricle	 fills,	 sarcomeres	 are	 stretched	 along	 the	 ascending	 limb	
of	the	length-	tension	relationship,	resulting	in	greater	myofilament	
force	generation	and	ejection	of	blood.	 In	pathological	conditions,	
such	as	heart	failure,	increased	resistance	to	ventricular	filling	may	
reduce	 end-	diastolic	 volumes	 and	 thereby	 cause	 a	 decrease	 in	
stroke	volume	and	cardiac	output.	This	limits	the	ability	of	the	heart	
to	respond	to	an	increase	in	demand,	which	is	a	definition	of	heart	
failure.	 Myocardial	 passive	 properties	 are	 implicated	 in	 diastolic	
Presented	at	 the	Cardiomyocyte	Mechano-	and	Myofilament	Dysfunction	 in	Heart	Failure	
Progression	Symposium	at	the	joint	AuPS	and	ASB	meeting,	Adelaide,	2016.	The	papers	in	
these	proceedings	were	peer	reviewed	under	the	supervision	of	the	AuPS	Editor.
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dysfunction.	During	normal	 filling,	a	major	contribution	 to	passive	
tension	is	thought	to	come	from	titin,	an	elastic	protein	that	spans	
half	of	the	sarcomere	from	Z-	disk	to	M-	line.	Changes	 in	the	prop-
erties	of	titin	in	disease	are	known	to	include	a	shift	in	isoform	dis-
tribution	from	the	more	compliant	N2BA	isoform	to	the	shorter	and	
stiffer	N2B	isoform,	oxidation	of	cysteine	residues,	and	phosphor-
ylation	status.1	The	extracellular	matrix	also	contributes	to	passive	
tension	 in	volume-	overload	 situations.	Proliferation	of	 collagen	 fi-
bres	(fibrosis)	and	greater	cross-	linking	between	fibres	can	increase	
myocardial	 stiffness2	 and	mechanisms	 involving	 the	myofilaments	
and	cytoskeleton	may	also	be	relevant.
In	addition,	metabolic	state	also	influences	cardiac	passive	proper-
ties.	Creatine	kinase	(CK)	catalyses	the	reversible	transfer	of	inorganic	
phosphate	from	creatine	phosphate	to	ADP,	generating	ATP.	
In	 cardiac	muscle	 there	 are	 four	 isoforms:	 CK-m	 (muscle)	 that	
accounts	 for	 about	70%	of	 total	CK,	of	which	10%-	30%	 is	 bound	
to	the	myofilament	protein	myomesin;	CK-	mt	(mitochondrial)	20%-	
30%	 total;	CK-b	 (brain)	 and	CK-mb	 (muscle/brain)	 are	both	 found	
in	 low	 abundance	 but	 have	 been	 reported	 to	 increase	 in	 disease.	
CK	is	located	in	areas	with	high	ATP	turnover	such	as	mitochondria,	
myofilaments,	sarcoplasmic	reticulum	and	sarcolemma.3	This	 func-
tional	coupling	with	ATPases	helps	maintain	a	high	 local	ATP:ADP	
essential	for,	e.g.	cross-	bridge	cycling	and	Ca2+	uptake.4,5	Indeed,	a	
consequence	of	ADP	accumulation	is	an	increase	in	passive	tension	
in	the	heart	due	to	rigor-	like	cross-	bridge	formation.6,7	CK	expres-
sion	decreases	in	left	heart	failure,8	which	may	have	multiple	reper-
cussions	in	the	cardiac	myocyte.
2  | PULMONARY ARTERY HYPERTENSION 
AND DIASTOLIC DYSFUNCTION
Pulmonary	 artery	 hypertension	 (PAH)	 is	 a	 complex	 disease	 with	
	interactions	between	the	pulmonary	vasculature	(PV)	and	the	right	
ventricle	(RV).	It	is	caused	by	increased	constriction	of	the	PV	which	
increases	vascular	resistance	and	hence	RV	afterload.	This	eventu-
ally	leads	to	RV	failure,	which	is	the	most	common	cause	of	death	
in	PAH.
In	 the	study	of	Rain	et	al9	human	PAH	patients	were	 found	 to	
have	 diastolic	 dysfunction.	There	was	 increased	 stiffness	 of	myo-
cardium,	 increased	 collagen	 content	 and	 reduced	phosphorylation	
of	titin	with	no	shift	in	titin	isoforms.	RV	failure	has	also	been	stud-
ied	 in	animal	models	of	PAH.10	 In	 the	monocrotaline	 rat	model	of	
PAH,	RV	heart	 failure	occurs	3-	4	weeks	after	 a	 single	 injection	of	
monocrotaline.	The	onset	of	heart	failure	in	this	model	was	associ-
ated	with	diastolic	dysfunction.11	When	a	 reduced	dose	of	mono-
crotaline	was	used	to	induce	stable	hypertrophy,	diastolic	function	
was	preserved.12
We	have	 used	 the	monocrotaline	 rat	model	 to	 study	 RV	 failure	
in	PAH.	The	end	diastolic	pressure–volume	relationship	(EDPVR)	was	
measured	 using	 a	 Millar	 catheter	 inserted	 into	 the	 RV	 of	 anesthe-
tized	animals.	The	EDPVR	was	significantly	steeper	in	monocrotaline-	
injected	rats	(MCT;	[FAIL	in	Fowler	et al.13])	compared	to	saline-	injected	
controls	(CON),	indicating	reduced	compliance	and	greater	resistance	
to	ventricular	filling	and	confirming	the	presence	of	diastolic	dysfunc-
tion.	This	was	not	linked	to	increased	fibrosis,	therefore	changes	in	the	
properties	of	single	ventricular	myocytes	were	investigated.
Intact	 single	myocytes	were	attached	 to	glass	 fibres	and	electri-
cally	stimulated	to	contract	while	being	stretched.	The	end	-	diastolic	
force-	length	 relationship	 (EDFLR)	 was	 recorded	 and	 the	 slope	 was	
found	 to	be	 significantly	 steeper	 in	RV	myocytes	 from	MCT	 rats,	 in	
accord	with	the	steeper	EDPVR	in	vivo.	Furthermore,	it	was	observed	
that	RV	myocytes	 (but	not	 left	ventricular	myocytes)	from	MCT	rats	
had	 significantly	 shorter	 diastolic	 sarcomere	 lengths	 compared	 to	
CON	animals,	 in	 the	absence	of	 changes	 in	either	diastolic	 intracel-
lular	 Ca2+	 (measured	 with	 Fura-	2)	 or	 myofilament	 Ca2+	 sensitivity.	
Application	of	an	intracellular	Ca2+-	buffer	(BAPTA-	AM)	increased	sar-
comere	length;	subsequent	addition	of	a	myofilament	cross-	bridge	in-
hibitor	(40	mmol	L−1	BDM)	caused	further	lengthening.	The	sarcomere	
lengthening	effect	of	BDM	was	significantly	greater	in	MCT	than	CON,	
suggesting	a	cross-	bridge	based,	Ca2+-	independent	mechanism.
Western	blot	 analysis	 showed	a	 significant	 reduction	 in	protein	
levels	of	CK	in	the	RV	of	MCT	rats.	Furthermore,	when	the	sarcolemma	
was	permeabilised	with	saponin	and	cells	incubated	with	exogenous	
CK	 and	 creatine	 phosphate,	 the	 sarcomere	 length	 of	 RV	myocytes	
from	MCT	rats	significantly	increased.	Conversely	in	CON	myocytes,	
inhibition	 of	 CK	 shortened	 sarcomere	 length.	 This	 indicated	 that	
loss	of	CK	in	MCT	myocytes	impaired	RV	diastolic	function.	In	intact	
CON	RV	myocytes,	 the	relationship	between	stimulation	frequency	
and	myocyte	shortening	was	relatively	flat	over	the	range	1-	7	Hz,	in	
contrast	 the	 relationship	 in	MCT	myocytes	was	steeply	negative.	A	
similar	steep	negative	relationship	occurred	in	CON	myocytes	follow-
ing	CK	inhibition.	We	interpreted	this	as	a	decreased	ability	of	MCT	
myocytes	to	respond	to	an	increase	in	demand,	which	is	a	definition	
of	heart	 failure.	We	concluded	 that	decreased	CK	expression	 leads	
to	 diastolic	 dysfunction,	 via	 local	 reduction	 in	 ATP:ADP	 ratio	 and	
thus	to	Ca2+-	independent	 force	production	and	diastolic	sarcomere	
shortening.13
3  | BETA- BLOCKER TREATMENT OF PAH
There	is	currently	no	cure	for	PAH	and	novel	treatments	are	needed	
to	 resolve	 this.	The	 importance	of	RV	 function	 in	PAH	patient	 sur-
vival	 indicates	 the	heart	 is	 a	potential	 therapeutic	 target.	However,	
available	therapies	primarily	cause	vasodilation	of	the	PV	and	current	
guidelines	do	not	include	treatments	specifically	for	the	RV.14	It	was	
proposed	that	established	treatments	for	left	ventricular	failure	may	
be	beneficial	to	the	failing	RV	in	PAH.15,16	Beta-	adrenoceptor	block-
ers	(beta-	blockers)	are	a	primary	treatment	for	left	ventricular	failure	
which	 slow	 the	 cardiac	 remodelling	 caused	 by	 chronic	 sympathetic	
activation.	Small	 clinical	 trials	have	 tested	 their	use	 in	PAH	without	
finding	adverse	effects.17
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Pre-	clinical	studies	have	shown	beta-	blockers	improved	animal	sur-
vival,	vascular	remodelling	and	cardiac	function	in	PAH.	However,	the	
mechanisms	contributing	to	improved	cardiac	function	have	not	been	
investigated.	We	therefore	proposed	the	first	study	to	investigate	the	
mechanisms	by	which	beta-	blockade	may	benefit	RV	myocytes	in	PAH.	
From	our	previous	findings,	discussed	in	the	preceding	section,	we	hy-
pothesized	that	beta-	blockade	would	improve	diastolic	dysfunction	and	
the	response	to	increased	demand	in	monocrotaline-	treated	rats,	and	
that	these	changes	would	be	associated	with		increased	levels	of	CK.
Experiments	 were	 conducted	 with	 local	 ethical	 approval	 and	
in	 accordance	 with	 UK	 Home	 Office	 and	 European	 Parliament	
Directive	2010/63/EU	guidelines	on	 the	use	of	animals	 in	 research.	
Methodological	details	can	be	found	in	Fowler	et	al13	PAH	and	RV	fail-
ure	were	induced	in	rats	by	a	single	IP	injection	(60	mg/kg)	of	mono-
crotaline.	When	PAH	was	established,	metoprolol	in	sucrose	solution	
(10	mg/kg	per	day,	MCT+BB)	or	sucrose	solution	(MCT)	was	admin-
istered	 by	 voluntary	 syringe	 feeding.	 Control	 animals	 (CON)	 were	
	injected	with	saline	and	given	sucrose.
As	 we	 were	 specifically	 interested	 in	 the	 cardiac	 effects	 of	
beta-	blocker	 treatment	we	 chose	 to	 use	metoprolol:	 it	 is	 beta-	1	
specific	 (the	 predominant	 beta-	adrenoceptor	 in	 heart),	 in	 com-
mon	clinical	use,	and	lacks	the	vasodilatory	effects	of	carvedilol18 
and nebivolol.19	The	human	equivalent	dose	of	10	mg/kg	per	day	
was	1.62	mg/kg	per	day,	within	the	typical	clinical	dose	range	for	
a	 75	kg	 patient	 (0.17-	2.67	mg/kg	 per	 day).	 Animals	 were	 killed	
when	showing	external	signs	of	heart	failure	(weight	loss,	lethargy,	
laboured	breathing,	piloerection)	(see	Fowler	et	al13).	Data	from	the	
three	 experimental	 groups	 were	 compared	 by	 one-	way	 ANOVA.	
Holm-	Sidak	 (n	numbers	equal)	 or	Tukey	 (n	numbers	uneven)	post 
hoc	 tests	were	 used	 following	 parametric	ANOVA,	 or	Dunn	 post 
hoc	 tests	 following	non-	parametric	ANOVA,	 as	 recommended	by	
the	statistical	package	 (GraphPad	Prism	7).	Statistical	differences	
are	reported	as	P < .05.
Treatment	with	metoprolol	delayed	the	median	time	to	the	onset	
of	 heart	 failure	 signs	 from	23	days	 post	MCT	 (n	=	12)	 to	 31	days	
(n	=	15)	(P	<	.01	Mantel-	Cox	test).	To	assess	the	mechanisms	of	BB	
action,	MCT	animals	were	compared	to	CON	and	MCT+BB	animals	
at	23	±	1	days	after	a	single	injection	of	saline	or	MCT.	Ventricular	
weights	are	given	in	Table	1	and	show	RV	hypertrophy	in	both	PAH	
groups.	EDPVRs	were	measured	in	anaethetised	rats	by	Millar	cath-
eter	 in	 the	RV	during	vena	 cava	 occlusion	 (Figure	1A,	 see	 Fowler	
et al.13	for	details	of	methodology).	The	EDPVR	from	MCT	animals	
was	 significantly	 steeper	 than	 CON,	 indicating	 diastolic	 dysfunc-
tion.	 The	 mean	 value	 for	 MCT+BB	 was	 intermediate	 (Figure	1B)	
representing	 an	 improvement	 in	 diastolic	 function.	 Consistent	
with	 observations	 in	whole	 animals,	 the	 resting	 sarcomere	 length	
of	RV	myocytes	showed	a	progressive	increase	CON	>	MCT+BB	>	
MCT	 (Figure	1C).	BB	 treatment	did	not	affect	diastolic	or	 systolic	
	pulmonary	 pressure,	 consistent	with	 previous	 reports	 using	 other	
BB18,19,	but	did		improve	the	ratio	of	end	systolic	pressure–volume	
relationship	(ESPVR)	to	arterial	elastance	(Ea),	an	indicator	of	in	vivo	
contractility/afterload	(see	Table	1).
TABLE  1 Animal	and	organ	characteristics	of	rats	on	the	median	day	of	heart	failure	signs	(CON	and	MCT+BB)	or	day	of	heart	failure	signs	
(MCT)
CON MCT MCT±BB
Rats/group 15 13 14
Organ	weights
Body	weight	(g) 301	±	6 257	±	4* 274	±	8*
Heart/body	weight	(mg/g) 3.65	±	0.16 4.82	±	0.23* 5.18	±	0.30*
Lung/body	weight	(mg/g) 4.76	±	0.39 8.74	±	0.46* 9.72	±	0.37*
RV/body	weight	(mg/g) 0.64	±	0.06 1.20	±	0.06* 1.14	±	0.06*
LV+S/body	weight	(mg/g) 2.20	±	0.10 2.55	±	0.13 2.58	±	0.09*
RV:LV+S	ratio 0.30	±	0.04 0.48	±	0.03* 0.45	±	0.02*
Rats/group 9 7 5
In vivo
End	systolic	pressure	(mm	Hg) 39.5	±	2.7 83.2	±	5.2* 101.8	±	9.9*
End	diastolic	pressure	(mm	Hg) 4.6	±	0.7 9.6	±	0.7* 9.9	±	2.3*
Stroke	volume	(μL) 110	±	10 48	±	10* 65	±	5*
ESPVR/Ea 0.93	±	0.27 0.27	±	0.06* 0.57	±	0.20
EDPVR	(mm	Hg/μL) 0.05	±	0.01 0.19	±	0.06* 0.09	±	0.02
On	the	final	experimental	day	there	was	RV	hypertrophy	in	MCT	and	MCT+BB	animals	compared	with	CON.	RV	systolic	and	diastolic	pressure	were	in-
creased	in	MCT	and	MCT+BB	animals.	Ventriculo-	arterial	coupling	was	impaired	in	MCT	(reduced	end-	systolic	pressure–volume	relationship	(ESPVR)	to	
arterial	elastance	(Ea)	ratio)	but	not	different	in	MCT+BB	compared	to	CON.
*P	<	.05,	one-	way	ANOVA.	 Intergroup	differences	between	variables	were	 identified	using	Dunn’s	 (RV:LV+S	and	End	systolic	pressure)	or	Tukey’s	 (all	
others)	post hoc	test.	CON,	control;	MCT,	monocrotaline	treated;	MCT+BB,	monocrotaline	+	beta-blocker	treated;	LV,	left	ventricle;	RV,	right	ventricle;	S,	
septum
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FIGURE 2 Loss	of	creatine	kinase	was	attenuated	by	BB	treatment.	(A),	Creatine	kinase	(CK)	isoenzyme	distribution	in	cardiac	muscle	consists	
of	70%	muscle	(CK-	m),	20%	mitochondrial	(CK-	mt)	and	the	remainder	brain	(CK-	b)	isoforms.	Expression	of	mRNA	for	the	predominant	CK	isoforms	
were	reduced	in	MCT+BB	and	MCT	rats	compared	to	CON.	Mean	values	for	MCT+BB	were	greater	than	MCT	but	not	statistically	so.	N	=	10	rats	
per	group.	One-	way	ANOVA	with	Holm-	Sidak	post hoc	test.	(B),	Western	blots	for	CK-	m	and	CK-	mt.	C,	CON;	B,	MCT+BB;	M,	MCT.	Common	CON	
samples	were	run	on	each	gel	as	calibrator	samples	where	N	precluded	use	of	a	single	gel.	Blots	were	stripped	and	re-	probed	for	GAPDH	hence	
changes	in	background	density.	Protein	levels	for	(C),	CK-	m	(N	=	6-	10	rats	per	group)	were	decreased	in	MCT	compared	to	CON,	levels	for	MCT+BB	
were	intermediate.	One-	way	ANOVA	with	Dunn’s	post hoc	test.	(D)	A	similar	trend	was	observed	in	CK-	mt	expression,	although	differences	were	not	
statistically	significant	(N	=	6-	7	rats	per	group).	Protein	levels	were	normalised	to	GAPDH	and	expressed	relative	to	the	mean	value	in	CON.	*P	<	0.05	
CON,	control;	MCT,	monocrotaline	treated;	MCT+BB,	monocrotaline	+	beta-blocker	treated
F IGURE  1 Beta-	Blocker	treatment	improves	EDPVR	and	increases	resting	sarcomere	length.	(A),	PV	relationships	from	a	CON	(black),	
MCT+BB	(blue)	and	MCT	(red)	animal.	The	EDPVR	was	recorded	during	progressive	vena	cava	occlusion.	The	loops	from	the	three	groups	are	
displaced	along	the	x-	axis	and	averaged	for	clarity.	(B),	There	was	a	significantly	steeper	EDPVR	in	MCT	(N	=	7	animals)	than	CON	(N	=	10	
animals)	(P	<	.05)	indicating	diastolic	dysfunction	in	MCT.	The	relationship	for	MCT+BB	(N	=	5	animals)	was	intermediate	indicating	an	
improvement	in	diastolic	function.	One-	way	ANOVA	with	Tukey	post hoc	test.	(C),	In	isolated	RV	myocytes	resting	sarcomere	length	progressively	
shortened	CON	>	MCT+BB	>	MCT	(n	=	30	cells	from	N	=	6	rats	per	group).	*	P	<	.05,	one-	way	ANOVA	with	Holm-	Sidak	post hoc	test.	CON,	
control;	MCT,	monocrotaline	treated;	MCT+BB,	monocrotaline	+	beta-blocker	treated;	EDPVR,	end-diastolic	pressure-volume	relationship
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Our	 previous	 observations	 had	 linked	 CK	 to	 these	 changes,	
Figure	2	shows	the	levels	of	mRNA	for	CK-	m	and	CK-	mt	(Figure	2A)	
were	significantly	reduced	in	MCT	vs	CON.	Protein	levels	for	CK-	m	
(Figure	2B,	C)	were	also	significantly	lower	in	MCT.	Consistent	with	
our	previous	report,	CK-	mt	tended	to	be	reduced	in	MCT	by	around	
20%	(Figure	2D).	There	were	no	significant	differences	in	the	levels	
of	 CK-	m	 and	 CK-	mito,	mRNA	 or	 protein	 levels	 between	MCT+BB	
and	MCT.	However,	 in	 each	of	 the	 four	 comparisons,	mean	values	
for	MCT+BB	were	 intermediate	between	CON	and	MCT	indicating	
a	trend	for	 improvement.	Furthermore,	we	have	presented	data	for	
CK	mRNA	and	protein	expression,	but	this	is	not	always	synonymous	
with	enzyme	activity,	particularly	if	the	in situ	environment	in	failing	
hearts	has	increased	oxidative	stress20	or	reduced	substrate	availabil-
ity,	both	of	which	are	thought	to	decrease	CK	activity.	It	is	interesting	
to	note	that	the	use	of	beta-	blockers	to	improve	CK	function	is	con-
sistent	with	previous	findings	in	a	model	of	myocardial	infarction.21
At	 low	 stimulation	 frequency	 (1	Hz)	MCT	myocytes	 had	 greater	
sarcomere	 shortening	 (Figure	3A)	 than	 CON	 and	 MCT+BB,	 which	
we	believe	 is	related	to	the	 longer	action	potential	duration	 in	MCT	
myocytes	promoting	greater	loading	of	Ca2+	stores.22	However,	when	
demand	was	increased	by	increasing	stimulation	frequency,	CON	my-
ocytes	 showed	a	positive	or	 flat	 contraction–frequency	 relationship	
compared	with	a	negative	relationship	in	MCT.	Myocytes	from	beta-	
blocker	treated	rats	had	an	intermediate	relationship,	such	that	frac-
tional	shortening	was	not	different	to	CON	at	any	frequency	and	was	
significantly	greater	than	MCT	at	7	Hz.
4  | CONCLUSIONS
Data	for	CON	and	MCT	groups	confirm	the	findings	from	our	previous	
study.13	In	addition,	we	show	that	parameters	modulated	by	PAH	consist-
ently	show	means	intermediate	to	CON	and	MCT	following	beta-	blocker	
therapy.	This	suggests	beta-	blocker	treatment	may	contribute	to	delaying	
the	onset	of	heart	 failure	by	reducing	maladaptive	cellular	 remodelling	
within	the	RV.	That	these	effects	on	the	myocardium	were	achieved	in	
the	absence	of	improvement	in	lung	weights	or	pulmonary	artery	pres-
sure	suggest	they	are	due	to	direct	effects	on	the	myocardium.	This	inter-
pretation	would	support	the	use	of	beta-	blockers	as	an	adjunct	to,	rather	
than	 a	 replacement	 for,	 conventional	 treatments	 for	PAH.	Despite	 in-
creasing	pre-	clinical	evidence	supporting	a	beneficial	effect	and	revealing	
their	mode	of	action,	the	use	of	beta-	blockers	to	treat	PAH	is	at	present	
controversial,17	and	further	data	from	clinical	trials	are	required.
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